NEW HAVEN - U.S. Sen. Chris Murphy has named BioXcel Therapeutics as â€śMurphyâ€™s Innovator of the Monthâ€ť for October.
â€śBioXcel Therapeutics is at the cutting edge of fusing human knowledge with AI to change lives of the patients using their therapies,â€ť said Murphy. â€śIâ€™m proud that theyâ€™ve chosen Connecticut as their home to conduct drug discovery research and look forward to watching them continue to grow in our state and the field of AI and medicine.â€ť
BioXcel is a clinical-stage biopharmaceutical company that utilizes a unique artificial intelligence (AI) that draws from machine learning and big data analytics along with expertise and intuition of human experience in drug development.
The company employs 25 people at their headquarters in New Haven.
â€śWe believe the combination of our expertise and our ability to generate therapeutic candidates in neuroscience and immune-oncology is unique to Connecticut and the pharmaceutical industry. New Haven has been the perfect location for BioXcel to recruit world-class talent, access biotech investors and partners and easily travel within the region. We look forward to continuing to grow in Connecticut,â€ť said Vimal Mehta, CEO and founder of BioXcel Therapeutics.
BioXcel Therapeutics has a unique re-innovation approach that utilizes the AI platform to look at existing drugs that may be generic, may be in phase 2 program or may have failed Phase 2 programs to see how a particular drug may be redirected for a development in diseases with substantial unmet medical needs.